Scholar Rock Holdings Corporation SRRK

Healthcare Biotechnology

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigatio...

NDAQ:SRRK - Post by User

Scholar Rock Holdings Corporation

<< Previous

Bullboard Posts

(14)
•••

Post by IronFocus77on Nov 29, 2024 8:51am

87 Views

Post# 36337138

Scholar Rock: A Biotech Acquisition Waiting to Happen?

Scholar Rock’s pipeline is gaining momentum, and the buzz is that Phase 2 results could attract acquisition interest. A 50% upside feels realistic if the data delivers. Biotech is all about the milestones, and MYNZ is no stranger to leveraging pivotal developments in diagnostics to build its reputation.

<< Previous

Bullboard Posts

Mink Ventures defines eight new high-priority drill targets